We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensor Test Indicates Early Inflammation in Oral Cavity

By LabMedica International staff writers
Posted on 28 Aug 2017
Researchers have developed a novel rapid test using chewing gum and the tongue as a 24/7 detector, potentially providing a diagnostic device that could be used by nearly “anyone, anywhere, anytime”. More...
Their first such gum was successful in using saliva samples to identify patients with dental implants who had early-stage inflammation due to bacterial infection. Expanding this platform technology to other diseases could also provide more efficient screening of large populations.

Dental implants occasionally entail complications: in the years after receiving an implant 6-15% of patients develop an inflammatory response caused by bacteria, in the worst case destroying the soft tissue and bone around the implant. When the new test will be available (planned for in 2-3 years), patients would benefit from a simple, quick, and affordable method to assess whether they carry such bacteria.

The gum test was developed by a pharmaceutical research team at Julius-Maximilians-University Würzburg (JMU, Wurzburg, Germany) to provide early detection aimed at preventing serious complications. "Anyone can use this new diagnostic tool anywhere and anytime without any technical equipment," said Prof. Lorenz Meinel of JMU, who co-led the development with Dr. Jennifer Ritzer. Initial proof-of-principle studies using saliva of patients were conducted at Merli Dental Clinic in Rimini.

The scientific background: In the presence of inflammatory conditions, specific protein-degrading enzymes (matrix metalloproteinases) are activated in the mouth. While chewing the gum, these enzymes also rapidly break down the special ingredient in gum: peptide sensors consisting of a protease cleavable linker in between a bitter substance and a microparticle. When the peptide is cleaved, the bitter tasting substance is released and detected by the tongue. Patients can then visit their dentist who confirms the diagnosis and treats the disease.

Chewing gum rapid tests for other medical applications are presently under development. "We hope to be able to diagnose other diseases with our “anyone, anywhere, anytime” diagnostics to identify and address these diseases as early as possible," said Prof. Meinel.

The study, by Ritzer J et al, was published August 15, 2017, in the journal Nature Communications.

Related Links:
Julius-Maximilians-University Würzburg


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.